SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 135,580.50 |
| Enterprise Value ($M) | 155,388.50 |
| Book Value ($M) | 19,078.00 |
| Book Value / Share | 15.32 |
| Price / Book | 7.11 |
| NCAV ($M) | -21,264.00 |
| NCAV / Share | -17.08 |
| Price / NCAV | -6.38 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.13 |
| Return on Assets (ROA) | 0.11 |
| Return on Equity (ROE) | 0.34 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.00 |
| Current Ratio | 1.30 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 16,092.00 |
| Assets | 56,434.00 |
| Liabilities | 37,356.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 28,754.00 |
| Operating Income | 10,869.00 |
| Net Income | 480.00 |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 10,828.00 |
| Cash from Investing | -3,449.00 |
| Cash from Financing | -3,433.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Capital World Investors | 4.30 | -35.68 | |
| 13G/A | BlackRock, Inc. | 8.20 | -17.14 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 1,999,166 | 8,316,452 | 24.04 | |
| 844,279 | 4,142,438 | 20.38 | |
| 1,182,894 | 4,350,189 | 27.19 | |
| 627,613 | 3,558,640 | 17.64 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| FGEN – FibroGen, Inc. | GBIO – Generation Bio Co. |
| GERN – Geron Corporation | GLUE – Monte Rosa Therapeutics, Inc. |
| GOSS – Gossamer Bio, Inc. |